In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

A new daily weight loss pill could be available soon – and a recent trial has shown that people taking the drug can shed kilos in weeks. Its release will offer people with obesity a new and convenient alternative to jabs.